|
|
|
| The application of Aptima HPV genotyping test in the triage of women with ASC-US |
| WANG Kaiyi, CHEN Yingying, DONG Jie. |
| Department of Gynecology, the Maternity and Child Health Care Hospital of Huzhou, Huzhou, 313000 |
|
| Cite this article: |
|
WANG Kaiyi,CHEN Yingying,DONG Jie.. The application of Aptima HPV genotyping test in the triage of women with ASC-US[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2018, 48(12): 913-916.
|
|
|
|
Abstract Objective: To investigate the clinical value of Aptima high risk human papillomavirus (hr-hpv) E6/E7 mRNA (Aptima HPV) and its genotyping (GT) test in women with atypical squamous cells of undetermined significance (ASC-US) cytology for cervical cancer screening. Methods: Aptima HPV and its genotyping (Aptima HPV-GT) of the cervical exfoliated cells were detected in 770 ASC-US women. HC2-HPV test, colposcopy and cervical biopsy were performed at the same time. Results: ①In 770 women, 83.1% of high-grade cervical lesions and cervical cancer (HSIL+49/59) were detected Aptima HPV positive; ②The OR value of Aptima HPV 16 positive female exposure risk was the highest, which was significantly higher than the risk of HSIL+ in Aptima HPV 18/45+, GT- and Aptima HPV- (P<0.05). Compared with HPV GT-, the incidence of HSIL+ in GT+ women increased significantly (P<0.05); ③The specificity of Aptima HPV for detection of HSIL+ was higher than that of HC2-HPV (P<0.05), but no significant difference was found in sensitivity, positive predictive value (PPV) and negative predictive value (NPV). Conclusion: In ASC-US women, Aptima HPV and its GT detection is a reliable and effective method for cervical lesion screening and risk delamination, especially for Aptima HPV 16 positive.
|
|
Received: 15 June 2018
|
| |
|
|
|
[1] SASLOW D, SOLOMON D, LAWSON H W, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer[J]. J Low Genit Tract Dis, 2012, 16(3): 175-204.
[2] LIU Q, LIN X, LIN L, et al. A comparative study of three different nucleic acid amplification techniques combined with microchip electrophoresis for HPV16 E6/E7 mRNA detection[J]. Analyst, 2015, 140(19): 6736-6741.
[3] SOLOMON D, DAVEY D, KURMAN R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology[J]. Jama, 2002, 287(16): 2114-2119.
[4] CUSCHIERI K, WENTZENSEN N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia[J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(10): 2536-2545.
[5] NESSA A, RASHID M H, JAHAN M, et al. Role of the HPV DNA test in follow-up of treated cervical intraepithelial neoplasia in Bangladesh[J]. Asian Pac J Cancer Prev, 2014, 15(19): 8063-8067.
[6] Haedicke J, Iftner T. A review of the clinical performance of the Aptima HPV assay[J]. J Clin Virol, 2016, 76 Suppl 1: S40-S48.
[7] REID J L, JR WRIGHT T C, STOLER M H, et al. Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study[J]. Am J Clin Pathol, 2015, 144(3): 473-483.
[8] 黄凌霄, 潘琼慧, 郑建琼, 等. HPV E6/E7 mRNA在CINII及以上病变中的诊断价值[J]. 温州医科大学学报, 2015, 45(8): 583-587. |
|
|
|
